RT Journal Article
SR Electronic
T1 Modification of Noradrenaline Release in Pithed Spontaneously Hypertensive Rats by I<sub>1</sub>-Binding Sites in Addition to  α<sub>2</sub>-Adrenoceptors
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 1063
OP 1071
DO 10.1124/jpet.102.044966
VO 304
IS 3
A1 Walter Raasch
A1 Britta Jungbluth
A1 Ulrich Schäfer
A1 Walter Häuser
A1 Peter Dominiak
YR 2003
UL http://jpet.aspetjournals.org/content/304/3/1063.abstract
AB It is known that moxonidine acts as an agonist at presynaptic α2-adrenoceptors of the postganglionic sympathetic nerve terminals and leads to a reduction in noradrenaline release. In addition, it is conceivable that I1-binding sites located in other regions of the pre- and postganglionic sympathetic neurons are involved in this effect. Our aim was to investigate whether and to what extent activation of the I1-binding sites contributes to the moxonidine-induced inhibition of noradrenaline release. Noradrenaline release was induced in pithed spontaneously hypertensive rats (pretreated with phenoxybenzamine/desipramine at 10/0.5 mg/kg) by stimulation of sympathetic overflow from the spinal cord. Noradrenaline overflow was reduced using moxonidine (0.18, 0.6, and 1.8 mg/kg) by 39.4, 70.4, or 78.7%, respectively, even when all α1-/α2-adrenoceptors were blocked effectively by phenoxybenzamine. In contrast, the I1-antagonist efaroxan (0.1, 1, and 3 mg/kg) increased noradrenaline overflow from 453 (control) to 1710, 1999, or 2754 pg/ml, suggesting an autoreceptor-like function of I1-binding sites. In consequence, moxonidine (0.18, 0.6, and 1.8 mg/kg) reduced the increase in noradrenaline overflow in efaroxan-treated animals (1 mg/kg) by 22.7, 41.7, and 50.5%, respectively. Agmatine (6 and 60 mg/kg), an endogenous agonist at I1-binding sites, reduced noradrenaline overflow (−36 or 53%), even under α2-adrenoceptor blockade. When 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane (AGN192403) (10 mg/kg) was injected, a selective blocker of I1-binding sites, noradrenaline overflow was not influenced by agmatine. It is concluded that moxonidine reduces noradrenaline overflow by acting at I1-binding sites in addition to its agonistic property at α2-adrenoceptors. The exact location of the I1-binding sites on the pre- or postsynaptic sympathetic neurons is unknown, but the location in the pre- or postsynaptic membrane of the sympathetic ganglion is the most plausible explanation. The American Society for Pharmacology and Experimental Therapeutics